Vermillion Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
29,504.00
22,965.00
18,642.00
5,242.00
5,539.00
9,360
Total Accounts Receivable
373.00
167.00
87.00
275.00
205.00
786
Inventories
-
-
87.00
93.00
102.00
92
Other Current Assets
372.00
534.00
550.00
498.00
459.00
550
Total Current Assets
30,249.00
23,666.00
19,366.00
6,108.00
6,305.00
10,788
Net Property, Plant & Equipment
391.00
508.00
1,504.00
1,911.00
1,181.00
608
Other Assets
-
-
90.00
-
11.00
12
Total Assets
30,640.00
24,174.00
20,960.00
8,019.00
7,497.00
11,408
ST Debt & Current Portion LT Debt
1,106.00
1,106.00
-
182.00
185.00
Accounts Payable
541.00
1,123.00
988.00
881.00
745.00
Income Tax Payable
-
-
40.00
-
-
Other Current Liabilities
1,911.00
2,690.00
2,323.00
1,498.00
1,679.00
Total Current Liabilities
3,558.00
4,919.00
3,351.00
2,561.00
2,609.00
Long-Term Debt
-
-
63.00
1,667.00
1,481.00
Other Liabilities
316.00
-
-
29.00
-
Total Liabilities
3,874.00
4,919.00
3,414.00
4,257.00
4,090.00
Common Equity (Total)
26,766.00
19,255.00
17,546.00
3,762.00
3,407.00
Total Shareholders' Equity
26,766.00
19,255.00
17,546.00
3,762.00
3,407.00
Total Equity
26,766.00
19,255.00
17,546.00
3,762.00
3,407.00
Liabilities & Shareholders' Equity
30,640.00
24,174.00
20,960.00
8,019.00
7,497.00

About Vermillion

View Profile
Address
12117 Bee Caves Road
Austin Texas 78738
United States
Employees -
Website http://www.vermillion.com
Updated 07/08/2019
Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. The company's bio-analytical solutions helps physicians diagnose, treat and improve gynecologic health outcomes for women.